Results 41 to 50 of about 179,740 (256)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

The COMPASS Experiment at CERN [PDF]

, 2007
The COMPASS experiment makes use of the CERN SPS high-intensitymuon and hadron beams for the investigation of the nucleon spin structure and the spectroscopy of hadrons. One or more outgoing particles are detected in coincidence with the incoming muon or
A. Amoroso, A. Braem, A. Bravar, A. Bressan, A. Chapiro, A. Cicuttin, A. Donati, A. Efremov, A. Ferrero, A. Giganon, A. Grasso, A. Grünemaier, A. Guskov, A. Janata, A. Korzenev, A. Lehmann, A. Maggiora, A. Magnon, A. Mann, A. Martin, A. Mielech, A. Mutter, A. Padee, A. Richter, A. Sandacz, A. Shaligin, A. Srnka, A. Teufel, A. Vossen, A. Zvyagin, A.A. Colavita, A.A. Lednev, A.A. Nozdrin, A.A. Popov, A.A. Shishkin, A.G. Olshevsky, A.G. Samartsev, A.I. Ioukaev, A.K. Konoplyannikov, A.M. Dinkelbach, A.M. Gorin, A.M. Kotzinian, A.M. Rozhdestvensky, A.M. Zanetti, A.N. Maximov, A.N. Sissakian, A.S. Korentchenko, A.V. Dolgopolov, Abazov, Abazov, Abbon, Abbon, Abragam, Abt, Albrecht, Albrecht, Albrecht, Albrecht, Albrecht, Albrecht, Albrecht, Albrecht, Alde, Alekseev, Alexeev, Alexeev, Alexeev, Altunbas, Altunbas, Angerer, Antipov, Astbury, B. Badełek, B. Gobbo, B. Grube, B. Ketzer, B. Parsamyan, B. Pawlukiewicz, Ball, Ball, Bass, Baum, Bencivenni, Bernet, Bernet, Binon, Binon, Binon, Bisplinghoff, Brown, Brun, Brückner, Busza, Bychkov, Bültmann, C. Bernet, C. d’Ambrosio, C. Franco, C. Heß, C. Ilgner, C. Marchand, C. Quintans, C. Schill, D. Demchenko, D. Durand, D. Kang, D. Kramer, D. Matthiä, D. Neyret, D. Panzieri, D. Piedigrossi, D. Reggiani, D. Ryabchikov, D. Seeharsch, D. Setter, D. Sora, D. Thers, D. von Harrach, D.V. Peshekhonov, Dael, Delagnes, Doble, E. Albrecht, E. Burtin, E. Delagnes, E. Kabuß, E. Rocco, E. Rondio, E. Weise, E.V. Komissarov, F. Balestra, F. Bradamante, F. Fratnik, F. Gautheron, F. Gougnaud, F. Haas, F. Hinterberger, F. Karstens, F. Klein, F. Kunne, F. Massmann, F. Molinié, F. Mota, F. Nerling, F. Robinet, F. Sauli, F. Simon, F. Sozzi, F. Stinzing, F. Tessarotto, F.H. Heinsius, Fischer, French, Frühwirth, G. Baum, G. Brona, G. Menon, G. Piragino, G. Pontecorvo, G. Reicherz, G. Tarte, G. Venugopal, G.D. Alexeev, G.I. Smirnov, G.K. Mallot, G.V. Khaustov, G.V. Krivokhizhin, Gaspar, Goertz, Gorin, Grube, H. Angerer, H. Fischer, H. Pereira, H. Santos, H. Schmitt, H. Wollny, H.-W. Siebert, Horikawa, I. Horn, I. Ivanchin, I. Konorov, I. Ludwig, I. Razaq, I.A. Savin, I.V. Manuilov, Iarocci, Ingelman, Ingelman, J. Ball, J. Barth, J. Bisplinghoff, J. Franz, J. Hannappel, J. Heckmann, J. Kiefer, J. Kubart, J. Lichtenstadt, J. Marroncle, J. Marzec, J. Nassalski, J. Pochodzalla, J. Polak, J. Pretz, J. Urban, J. Zhao, J.-F. Rajotte, J.H. Koivuniemi, J.M. Friedrich, J.M. Gheller, J.M. Le Goff, J.Y. Roussé, K. Klimaszewski, K. Kondo, K. Kowalik, K. Kurek, K. Königsmann, K. Platzer, K. Zaremba, Ketzer, Ketzer, Kobayashi, Koivuniemi, Kondo, Kunne, Kurek, L. Dhara, L. Ferrero, L. Gatignon, L. Masek, L. Ropelewski, L. Schmitt, L. Silva, L. Sinha, L.G. Tkatchev, Lednev, Lounasmaa, M. Becker, M. Bettinelli, M. Bosteels, M. Chalifour, M. Chiosso, M. Colantoni, M. Faessler, M. Finger, M. Finger, M. Giorgi, M. Lamanna, M. Leberig, M. Maggiora, M. Niebuhr, M. Ostrick, M. Sans Merce, M. Seimetz, M. Slunecka, M. Stolarski, M. Sulc, M. Virius, M. von Hodenberg, M. Wagner, M. Wiesmann, M. Zavertyaev, M. Ziembicki, M.A. Moinester, M.G. Alekseev, M.G. Sapozhnikov, M.L. Crespo, M.P. Bussa, N. Dedek, N. Dibiase, N. Doshita, N. d’Hose, N. Horikawa, N. Takabayashi, N.A. Koutchinski, N.A. Kuzmin, N.I. Jouravlev, N.P. Kravchuk, N.V. Vlassov, Neliba, Newcomer, O. Ivanov, O. Kouznetsov, O. Nähle, O.A. Grajek, O.P. Gavrichtchouk, O.Yu. Denisov, O.Yu. Shevchenko, P. Abbon, P. Berglund, P. Bordalo, P. Ciliberti, P. Cristaudo, P. Deck, P. Fauland, P. Pagano, P. Rebourgeard, P. Schiavon, P. Schönmeier, P.D. Eversheim, Palmieri, Platzer, Pobell, Pyrlik, Q. Weitzel, R. Bertini, R. Birsa, R. De Masi, R. Garfagnini, R. Geyer, R. Hagemann, R. Hermann, R. Jahn, R. Joosten, R. Kuhn, R. Sulej, R. Valbuena, R. Webb, R. Windmolders, R. Ziegler, S. Costa, S. Dalla Torre, S. Das, S. Gerassimov, S. Goertz, S. Grabmüller, S. Hedicke, S. Horikawa, S. Ishimoto, S. Koblitz, S. Levorato, S. Neliba, S. Panebianco, S. Paul, S. Platchkov, S. Procureur, S. Ramos, S. Sosio, S. Tessaro, S. Trippel, S. Wirth, S.S. Dasgupta, S.V. Donskov, Sauli, Sjöstrand, T. Dafni, T. Hasegawa, T. Iwata, T. Liska, T. Matsuda, T. Nagel, T. Niinikoski, T. Schmidt, T. Toeda, Thers, U. Fuchs, U. Wiedner, V. Diaz, V. Duic, V. Falaleev, V. Frolov, V. I Lyashenko, V. Kalinnikov, V. Kukhtin, V. Levinski, V.A. Anosov, V.A. Dorofeev, V.A. Polyakov, V.D. Peshekhonov, V.D. Samoylenko, V.F. Konstantinov, V.I. Nikolaenko, V.N. Bytchkov, V.N. Kolosov, V.P. Sugonyaev, V.V. Tchalishev, V.V. Tokmenin, V.Yu. Alexakhin, van der Bij, Vlasov, W. Dünnweber, W. Eyrich, W. Kastaun, W. Meyer, W. Schroeder, W. Wiślicki, Wolin, Y. Bedfer, Y.L. Zlobin, Ypsilantis, Yu. Alexandrov, Yu. Kisselev, Yu.A. Khokhlov, Yu.V. Mikhailov, Z.V. Kroumchtein   +394 more
core   +3 more sources

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Analogue P300-based BCI pointing device [PDF]

, 2006
We propose a P300-based BCI mouse. The system is analogue: the pointer is controlled by directly combining the amplitudes of the outputs produced by a filter in the presence of different stimuli.
Cinel, C, Citi, L, Poli, R
core   +1 more source

Time-reversed two-photon interferometry for phase super-resolution [PDF]

, 2013
We observed two-photon phase super-resolution in an unbalanced Michelson interferometer with classical Gaussian laser pulses. Our work is a time-reversed version of a two-photon interference experiment using an unbalanced Michelson interferometer.
Kitano, Masao, Kobayashi, Hirokazu, Nakanishi, Toshihiro, Ogawa, Kazuhisa, Tamate, Shuhei   +4 more
core   +2 more sources